| h-48d1115a | Dual-Receptor Antibody Shuttling | 0.80 | 0.45 | | validated | 2026-04-13 | |
| h-d47c2efa | Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents | 0.80 | 0.52 | AQP4 and ACSL4 (key ferroptosis regulator) | validated | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-var-d04a952932 | Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration | 0.80 | 0.74 | AIM2, CASP1, IL1B, PYCARD | validated | 2026-04-05 | SDA-2026-04-01-gap-20260401-225149 |
| h-593b3464 | ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2 to Protect Synaptic | 0.80 | 0.75 | CYP2J2/ω-3 DHA epoxides (sEH inhibition) | validated | 2026-04-25 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| h-alsmnd-01446b71d93 | MATR3 Nuclear Body Disruption Impairs RNA Processing Hubs and Triggers Splicing | 0.80 | 0.75 | MATR3,U1 snRNP,SNRPB,SNRNP70, splicing machinery,spliceosome | validated | 2026-04-27 | |
| h-7d24e096 | CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification | 0.80 | 0.80 | sTREM2/membrane-TREM2/ADAM10 | validated | 2026-04-15 | SDA-2026-04-26-trem2-showcase |
| h-var-22c38d11cd | ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degen | 0.80 | 0.87 | ACSL4 | validated | 2026-04-05 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-var-261452bfb4 | 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively | 0.80 | 0.87 | ACSL4 | validated | 2026-04-05 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-6b3f1b4b3e | Lysosomal GBA1 Enhancement via Glucosylceramide Reduction | 0.80 | 0.88 | GBA1 | proposed | 2026-05-04 | SDA-2026-05-04-gap-test-20260425-224949 |
| h-cross-synth-nlrp3- | NLRP3 inflammasome amplification across AD and PD proteinopathy | 0.80 | 0.79 | NLRP3 | validated | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-7e9718dbda | pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery | 0.80 | 0.33 | TFRC (TfR1); endosomal acidification pathway | validated | 2026-04-22 | SDA-2026-04-02-gap-bbb-antibody-transport |
| h-f32ba823 | Hypothesis 1: MANF/CDNF Signaling as Primary Neuroprotective Effector | 0.80 | 0.52 | MANF, CDNF | proposed | 2026-04-17 | SDA-2026-04-26-gap-pubmed-20260410-170057-a2f72fd8-debate |
| h-48858e2a | Microglial TREM2-SYK Pathway Enhancement | 0.80 | 0.70 | TREM2 | promoted | 2026-04-13 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-var-ee70969116 | Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with r | 0.80 | 0.45 | PVALB | proposed | 2026-04-07 | SDA-2026-04-03-26abc5e5f9f2 |
| h-cross-synth-pink1- | PINK1/Parkin mitophagy failure across PD, AD, and ALS | 0.80 | 0.78 | PINK1;PARK2 | active | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-436ff37203 | LRRK2 G2019S Kinase Inhibition for Parkinson's Disease | 0.80 | 0.85 | LRRK2 | proposed | 2026-05-06 | SDA-2026-05-06-gap-test-20260425-224949 |
| h-11795af0 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | 0.79 | 0.30 | APOE | promoted | 2026-04-02 | sda-2026-04-01-gap-010 |
| h-3fcd326bc1 | HDAC6 Inhibition for Charcot-Marie-Tooth Disease and ALS | 0.79 | 0.80 | HDAC6 | proposed | 2026-05-06 | SDA-2026-05-06-gap-test-20260425-224949 |
| h-a9f2570b | Targeting SASP-Complement Amplification Through HIF-1α Downstream Effectors | 0.79 | 0.68 | C1QA, C1QB, C3, IL1B | promoted | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88 |
| h-3f02f222 | Senescent Microglia Resolution via Maresins-Senolytics Combination | 0.79 | 0.60 | BCL2L1 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-d4ac0303f6 | G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying ly | 0.79 | 0.32 | LRRK2 | proposed | 2026-04-24 | SDA-2026-04-25-gapdebate-9180363b7c |
| h-da9af6a77a | NMN Supplementation Restores SIRT1/p66Shc/FOXO3 Epigenetic Axis and Dopaminergic | 0.79 | 0.73 | SIRT1/NAD+ axis | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| h-f3fb3b91 | Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming | 0.79 | 0.60 | TLR4 | proposed | 2026-04-02 | SDA-2026-04-01-gap-20260401-225149 |
| SDA-2026-04-02-gap-t | VCP-Mediated Autophagy Enhancement | 0.79 | 0.53 | VCP | proposed | 2026-04-16 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| hyp-SDA-2026-04-12-2 | Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology | 0.79 | 0.55 | CHRNA7 (α7 nicotinic receptor), BACE1 | debated | 2026-04-12 | SDA-2026-04-12-20260411-082446-2c1c9e2d |
| h-d0a564e8 | Competitive APOE4 Domain Stabilization Peptides | 0.78 | 0.30 | APOE | promoted | 2026-04-02 | sda-2026-04-01-gap-010 |
| h-ecd9ed6c | Integrated Biomarker Panel for Therapeutic Window Identification | 0.78 | 0.68 | CHI3L1 | promoted | 2026-04-15 | SDA-2026-04-15-gap-debate-20260410-112330-9abf86eb |
| h-var-d98a992599 | Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa | 0.78 | 0.72 | SST | proposed | 2026-04-05 | SDA-2026-04-03-26abc5e5f9f2 |
| hyp-lyso-snca-1d58cf | LAMP2A Liquid-Liquid Phase Separation Defects in Dopaminergic Neurons Create Sel | 0.78 | 0.68 | LAMP2 | active | 2026-04-27 | |
| h-807d7a82 | SASP-Driven Aquaporin-4 Dysregulation | 0.78 | 0.70 | AQP4 | promoted | 2026-04-02 | sda-2026-04-01-gap-013 |
| h-de0d4364 | Selective Acid Sphingomyelinase Modulation Therapy | 0.78 | 0.80 | SMPD1 | promoted | 2026-04-02 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| SDA-2026-04-02-gap-t | TREM2-mediated microglial tau clearance enhancement | 0.78 | 0.67 | TREM2 | proposed | 2026-04-16 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-cross-synth-stress | Stress-granule RNA-binding protein phase transition across ALS and FTD | 0.78 | 0.74 | TIA1;HNRNPA1;HNRNPA2B1 | active | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-9923279def | PINK1/Parkin–TREM2 Axis: Convergent Mitophagy Failure Unifies PD (SNCA/αSyn) and | 0.78 | 0.72 | PINK1,PRKN,TREM2,STUB1,NDUFS7 | proposed | 2026-04-27 | |
| h-7000ac15c1 | Therapeutic Window Exists Because Amplified Signals (Not Baseline) Drive Pathoge | 0.78 | 0.78 | LRRK2 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-dec9f2e970 | NLRP3 Inhibition (H7): Downstream Inflammatory Reversal | 0.78 | 0.78 | NLRP3/NLRP3 (NLRP3 inflammasome) | proposed | 2026-04-25 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| h-17d177c62b | Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing | 0.78 | 0.78 | AQP4, orexin receptor (HCRTR1/2) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-7bcf4b6c |
| h-6df1bc66 | Biphasic Ketogenic Intervention Protocol | 0.78 | 0.50 | HMGCS2 | proposed | 2026-04-16 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-810ec0eb | TFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis | 0.78 | 0.52 | TFEB, MTOR | promoted | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88 |
| h-var-f96e38ec20 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlie | 0.78 | 0.82 | ACSL4 | superseded | 2026-04-05 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-67914e81 | PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes | 0.78 | 0.68 | PDE4A, PDE4B, PDE4D | promoted | 2026-04-13 | SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9 |
| h-0e675a41 | Selective HDAC3 Inhibition with Cognitive Enhancement | 0.78 | 0.80 | HDAC3 | promoted | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-26b9f3e7 | SIRT1/PGC-1α Axis Activation to Preserve Mitochondrial Resiliency Against Microb | 0.78 | 0.76 | SIRT1, PGC-1α (PPARGC1A), NAMPT | promoted | 2026-04-16 | SDA-BIOMNI-MICROBIO-337ee37a |
| h-ae1b2beb | Transcriptional Autophagy-Lysosome Coupling | 0.78 | 0.71 | FOXO1 | promoted | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-ec5db48878 | Gamma entrainment reactivates PV+ interneuron ensembles to restore inhibition/ex | 0.78 | 0.88 | PV+ interneuron populations; GABRA1, GABRA5 (GABA-A α1, α5 s | proposed | 2026-04-28 | SRB-2026-04-28-h-bdbd2120 |
| h-var-600b3e39aa | APOE4-Specific Proteolytic Fragment Inhibition Therapy | 0.78 | 0.65 | APOE | proposed | 2026-04-16 | |
| h-var-e4cae9d286 | LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine | 0.78 | 0.82 | LPCAT3 | debated | 2026-04-05 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| hyp-lyso-snca-3429d8 | Exosomal SNCA Propagation from Lysosome-Compromised Neurons Contains a Distinct | 0.78 | 0.70 | SNCA | active | 2026-04-27 | |
| h-cross-synth-tbk1-o | TBK1-OPTN-p62 selective autophagy failure across ALS, FTD, and PD-like proteotox | 0.78 | 0.73 | TBK1 | active | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-7597968b | CX3CR1-TREM2 Integration for Synapse Pruning Normalization | 0.78 | 0.52 | CX3CR1-TREM2 | proposed | 2026-04-16 | SDA-2026-04-01-gap-001 |